GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Medexus Pharmaceuticals Inc (TSX:MDP) » Definitions » Capex-to-Operating-Cash-Flow

Medexus Pharmaceuticals (TSX:MDP) Capex-to-Operating-Cash-Flow : 0.02 (As of Dec. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Medexus Pharmaceuticals Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Medexus Pharmaceuticals's Capital Expenditure for the three months ended in Dec. 2024 was C$-0.15 Mil. Its Cash Flow from Operations for the three months ended in Dec. 2024 was C$9.56 Mil.

Hence, Medexus Pharmaceuticals's Capex-to-Operating-Cash-Flow for the three months ended in Dec. 2024 was 0.02.


Medexus Pharmaceuticals Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Medexus Pharmaceuticals's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medexus Pharmaceuticals Capex-to-Operating-Cash-Flow Chart

Medexus Pharmaceuticals Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 2.13 - - 0.01

Medexus Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.14 - 0.37 0.02

Competitive Comparison of Medexus Pharmaceuticals's Capex-to-Operating-Cash-Flow

For the Drug Manufacturers - Specialty & Generic subindustry, Medexus Pharmaceuticals's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medexus Pharmaceuticals's Capex-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Medexus Pharmaceuticals's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Medexus Pharmaceuticals's Capex-to-Operating-Cash-Flow falls into.


;
;

Medexus Pharmaceuticals Capex-to-Operating-Cash-Flow Calculation

Medexus Pharmaceuticals's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Mar. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-0.36) / 25.331
=0.01

Medexus Pharmaceuticals's Capex-to-Operating-Cash-Flow for the quarter that ended in Dec. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-0.148) / 9.56
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medexus Pharmaceuticals  (TSX:MDP) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Medexus Pharmaceuticals Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Medexus Pharmaceuticals's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Medexus Pharmaceuticals Business Description

Traded in Other Exchanges
Address
10 King Street East, Suite 600, Toronto, ON, CAN, M5C 1C3
Medexus Pharmaceuticals Inc is a specialty pharmaceutical company with a powerful North American commercial platform and a growing portfolio of inventive and rare disease treatment solutions. The company's focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology.
Executives
Brendon Buschman Senior Officer
Mike Mueller Director
Benoit Gravel Director
Stephen William Nelson Director
Kenneth D'entremont Director, Senior Officer
Marcel Pascal Konrad Senior Officer
Brian Peters Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)
Roland Boivin Senior Officer
Michael Pine Senior Officer
Glenn Tate Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)
Richard Labelle Senior Officer
Benoît Hébert Senior Officer